Alexion Pharmaceuticals
Develops and manufactures treatments for rare and ultra-rare diseases.
Company facts
- Founded
- 1992
- Employees
- 5,000
- Headquarters
- United States
- Type
- Private
- Funding
- Corporate Round · $39B · 2021
- Subsidiaries
- LogicBio Therapeutics, Amolyt Pharma, Syntimmune, Portola Pharmaceuticals, Achillion Pharmaceuticals
About
Alexion Pharmaceuticals, a global biopharmaceutical company headquartered in Boston, specializes in developing life-changing therapies for rare diseases. Building on more than three decades of expertise, the company translates complex biology—particularly the complement system—into innovative treatments across hematology, nephrology, neurology, and metabolic disorders. As a strategic partner of AstraZeneca Rare Disease, Alexion leverages a diversified pipeline and cutting-edge modalities to address unmet medical needs worldwide. Its commitment to accelerating discovery, combined with a patient-centric culture and expanding global footprint, distinguishes Alexion as a leader in rare-disease therapeutics.